Anxiety is a common issue encountered in most psychological disorders (Özakkaş, 2014) and can have numerous disturbing effects on both the mind and body. From a psychological perspective, symptoms such as difficulty concentrating, sleep disturbances, restlessness, and memory confusion are frequently observed. Physiologically, it manifests in symptoms like increased muscle tension, difficulty swallowing, dry mouth, abnormal bowel activity (either decreased or increased), heart palpitations, and erectile dysfunction, primarily caused by heightened activity in the sympathetic nervous system.
Generalized Anxiety Disorder (GAD)
Generalized anxiety disorder is a prevalent yet often poorly defined condition. It was recognized as a separate diagnostic category in the late 20th century with the DSM-III. It may be considered in individuals who do not meet the criteria for other anxiety disorders. GAD is also regarded as a risk factor for depression and other anxiety disorders. Characterized by both psychological and physiological symptoms, GAD often includes concentration difficulties, a persistent sense of worry, and restlessness. Individuals suffering from GAD may experience most of the symptoms throughout their lives and gradually become accustomed to them. Alongside recurrent anxious moods, physical symptoms are also present, primarily stemming from heightened activity in the autonomic nervous system and muscular tension.
Individuals with GAD frequently seek medical attention for their physical rather than psychological symptoms. The intensity of symptoms may vary over time, experiencing periods of exacerbation and remission. The prevalence of GAD is estimated to be around 5.8% in the general population (Roy-Byrne & Wagner, 2004). Studies indicate that it is more common in women than men, possibly due to women’s heightened sensitivity to life stressors and the hormonal and psychological changes experienced during menstruation.
GAD is often accompanied by comorbid conditions. The negative impact of anxiety symptoms on general health is considered a major contributing factor to comorbidity. Research shows that the comorbidity rate for Axis I psychiatric disorders in individuals with GAD is as high as 81% (Stein, 2004).
GAD typically follows a recurrent and chronic course. As with many psychological disorders, the trajectory of the illness often depends on how the previous episode progressed. Negative experiences during earlier treatment phases are usually predictive of a poor prognosis. The longer and more intense the symptoms, the poorer the prognosis tends to be. Among anxiety disorders, GAD is associated with the worst prognosis (Kessler, 1999), particularly when co-occurring with other psychological conditions. Despite its higher prevalence in women, gender has not been found to significantly affect the prognosis (Howell, 2001). Early onset of GAD can adversely affect career planning, social interactions, and academic achievement. Factors such as family dynamics, romantic relationships, and socialization levels also influence the prognosis.
Coping Strategies
For individuals with GAD, it is essential to provide psychoeducation about the nature of the disorder, coping mechanisms, and the fact that it is treatable (Nutt, 2001). Treatment goals include reducing anxiety and enabling the individual to maintain daily life despite ongoing symptoms (Sevinçok, 2007). Emotional and psychological states, accompanying cognitions and reactions, and the severity and level of physiological symptoms such as muscle tension and autonomic arousal must be evaluated.
Therapeutic strategies include psychological regulation, reassuring the individual, explaining the physiological symptoms, and assessing underlying conflicts. Considering the clinical course of GAD, strengthening coping mechanisms may reduce the need for medication, thereby lowering the associated individual and societal costs. However, when necessary, pharmacological treatment should not be disregarded and must be prescribed by a medical professional.
Confronting the anxiety-provoking situation too early in the treatment process may intensify symptoms. Therefore, clinicians should begin by addressing external factors contributing to the individual’s anxiety and help create a more manageable environment with the support of the patient and their surroundings. (Note: Detailed therapeutic techniques are beyond the scope of this article and are presented here in general terms.)
Conclusion
Current literature indicates that GAD has a poor prognosis. Its high comorbidity rate necessitates a multidisciplinary approach in both diagnosis and treatment. Clinical observations show that many factors associated with poor prognosis can lead to chronicity if left untreated or unsupported by appropriate interventions. Inclusion of generalized anxiety disorder as a subcategory in the anxiety disorders classification has improved recognition and awareness, leading to earlier diagnosis and treatment opportunities.
Future research and the development of effective coping strategies may help improve prognosis over time. These strategies typically involve psychoeducation, individual therapy techniques, and, if necessary, pharmacological treatment. Recognizing anxiety symptoms, understanding physiological responses, and developing skills to manage internal conflicts are important not only for personal well-being but also for social functionality. Therefore, early diagnosis, holistic treatment approaches, and environmental support are fundamental to effectively combat this disorder.
DSM-V Diagnostic Criteria for Generalized Anxiety Disorder
A. Excessive anxiety and worry (apprehensive expectation) occurring more days than not for at least six months, about various events or activities (e.g., work or school performance).
B. The individual finds it difficult to control the worry.
C. The anxiety and worry are associated with three (or more) of the following six symptoms (only one item required in children):
-
Restlessness or feeling keyed up or on edge
-
Being easily fatigued
-
Difficulty concentrating or mind going blank
-
Irritability
-
Muscle tension
-
Sleep disturbance (difficulty falling or staying asleep, or restless, unsatisfying sleep)
D. The anxiety, worry, or physical symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
E. The disturbance is not attributable to the physiological effects of a substance (e.g., a drug of abuse, medication) or another medical condition (e.g., hyperthyroidism).
F. The disturbance is not better explained by another mental disorder (e.g., panic disorder, OCD, social anxiety disorder).
References
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Publishing.
Balcıoğlu, İ., & Ünsalver, B. (2006). Generalized anxiety disorder: Epidemiology, prognosis, and non-pharmacological treatments. Cerrahpaşa Medical Journal, 37(3), 115–120.
Howell, H. B., Brawman-Mintzer, O., Monnier, J., & Yonkers, K. A. (2001). Generalized anxiety disorder in women. Psychiatric Clinics of North America, 24, 165–178.
Kessler, R. C., DuPont, R. L., Berglund, P., & Wittchen, H. U. (1999). Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. American Journal of Psychiatry, 156, 1915–1923.
Stein, M. B. (2004). Public health perspectives on generalized anxiety disorder. Journal of Clinical Psychiatry, 65(Suppl 13), 3–7.
Nutt, D., Argyropoulos, S., & Forshall, S. (2001). Generalized Anxiety Disorder: Diagnosis, Treatment and Its Relationship to Other Anxiety Disorders. London: Martin Dunitz.
Özakkaş, T. (2014). Anxiety disorders and their treatment.
Roy-Byrne, P. P., & Wagner, A. (2004). Primary care perspectives on generalized anxiety disorder. Journal of Clinical Psychiatry, 65(Suppl 13), 20–26.
Sevinçok, L. (2007). The neurobiology of generalized anxiety disorder. Klinik Psikiyatri, 10(5), 3–12.